Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
QNRX moved a median of -0.14% 30 minutes after news, and -0.86% by the close. How QNRX actually reacts to news — the realized, point-in-time move the market made, measured across 280 labeled events over the last three years with zero look-ahead.
QNRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 220 |
| 30-min | -0.14% | 41% | 242 |
| 60-min | -0.42% | 42% | 264 |
| to close | -0.86% | 41% | 277 |
| Middle 50% of QNRX reactions | -2.95% to +1.53% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 280 |
Half of all Quoin Pharmaceuticals, Ltd. - American Depositary Shares news events land between -2.95% and +1.53% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when QNRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to QNRX's baseline. Nothing else.
Recent QNRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy | Press release | GlobeNewswire | — | — | |
| Form 8-K Quoin Pharmaceuticals For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -4.87% | -0.24% | |
| Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome | Press release | GlobeNewswire | -4.87% | -0.24% | |
| Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy | Press release | GlobeNewswire | -2.90% | +5.36% | |
| Form DEF 14A Quoin Pharmaceuticals For: Nov 12 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.55% | |
| Form EFFECT Quoin Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | -0.47% | -18.32% | |
| Form 8-K Quoin Pharmaceuticals For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.53% | |
| Form PRE 14A Quoin Pharmaceuticals For: Nov 12 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -4.53% | |
| Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome | Press release | GlobeNewswire | +0.00% | +0.43% | |
| Form S-3 Quoin Pharmaceuticals | SEC filing · Form S-3 | SEC EDGAR | +1.19% | -0.14% | |
| Form 8-K Quoin Pharmaceuticals For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.16% | |
| Form D Quoin Pharmaceuticals | SEC filing · Form D | SEC EDGAR | +0.00% | -1.16% | |
| Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU | Press release | GlobeNewswire | -1.01% | +0.88% | |
| CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome | Press release | GlobeNewswire | -0.18% | -0.83% | |
| Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome | Press release | GlobeNewswire | +0.27% | -2.46% | |
| Form 8-K Quoin Pharmaceuticals, For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -5.04% | -11.94% | |
| Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million | Press release | GlobeNewswire | +9.70% | -15.23% | |
| Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome | Press release | GlobeNewswire | +9.70% | -15.23% | |
| Form 8-K Quoin Pharmaceuticals, For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | — | +11.96% | |
| Form 10-Q Quoin Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +9.03% | |
| Form 8-K Quoin Pharmaceuticals, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.03% | |
| Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -5.60% | +1.80% | |
| Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form ARS Quoin Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | -2.35% | |
| Form DEF 14A Quoin Pharmaceuticals, For: Aug 20 | SEC filing · Form DEF | SEC EDGAR | — | -2.35% | |
| Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome | Press release | GlobeNewswire | -0.11% | +0.86% | |
| Form PRE 14A Quoin Pharmaceuticals, For: Aug 20 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +5.26% | |
| Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome | Press release | GlobeNewswire | -2.15% | +4.09% | |
| Form 8-K Quoin Pharmaceuticals, For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -2.32% | -11.14% | |
| Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome | Press release | GlobeNewswire | -0.95% | -22.62% | |
| Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 | Press release | GlobeNewswire | — | -0.43% | |
| Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program | Press release | GlobeNewswire | -7.48% | -7.28% | |
| Form 8-K Quoin Pharmaceuticals, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.44% | |
| Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome | Press release | GlobeNewswire | +0.00% | -0.69% | |
| Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome | Press release | GlobeNewswire | +0.00% | -5.59% | |
| Form 10-Q Quoin Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.45% | +1.59% | |
| Form 8-K Quoin Pharmaceuticals, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | — | -6.61% | |
| Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -6.35% | -4.78% | |
| Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 | Press release | GlobeNewswire | -0.67% | +8.54% | |
| CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs | Press release | GlobeNewswire | — | +3.81% | |
| Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs | Press release | GlobeNewswire | +1.48% | +0.55% | |
| Form 10-K Quoin Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.05% | -13.49% | |
| Form 8-K Quoin Pharmaceuticals, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -3.89% | -13.54% | |
| Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Press release | GlobeNewswire | -6.22% | -18.92% | |
| Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome | Press release | GlobeNewswire | -9.88% | -6.55% | |
| Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 | Press release | GlobeNewswire | +3.77% | +11.17% | |
| Form 8-K Quoin Pharmaceuticals, For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +2.44% | -1.34% | |
| Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome | Press release | GlobeNewswire | +1.51% | -1.28% | |
| NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome | Press release | GlobeNewswire | +3.19% | +0.59% | |
| Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome | Press release | GlobeNewswire | +0.00% | -2.58% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the QNRX section they belong to.
Where else QNRX is measured.
QNRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Quoin Pharmaceuticals, Ltd. - American Depositary Shares's median reaction calculated?
Every labeled QNRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 280 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of QNRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does QNRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.